diclofenac has been researched along with Cardiac Failure in 15 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed a multivariate analysis of 34 701 patients with arthritis receiving etoricoxib 60 or 90 mg, or diclofenac 150 mg, daily for a mean of 18 months, to assess the incidence of confirmed, adjudicated CHF events resulting in emergency room visit or hospitalization." | 9.14 | Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. ( Brater, DC; Cannon, CP; Curtis, SP; Kaur, A; Krum, H; Laine, L; Smugar, SS; Wang, H; Weir, MR, 2009) |
| "Non-steroidal anti-inflammatory drugs (NSAID) or high doses of aspirin (acetylsalicylic acid) can exert detrimental effects on renal function and counteract the beneficial effects of angiotensin-converting enzyme (ACE) inhibitors in patients with congestive heart failure." | 9.11 | Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ACE-inhibitors. ( Björkman, S; Fyge, A; Gunnarsson, B; Höglund, P; Juhlin, T; Roth, B, 2004) |
| "We evaluated the relationship between baseline BP and change in BP on CV events (CVEs) in patients receiving NSAIDs or COX-2 inhibitors in the prospective randomized, double-blind, Multinational Etoricoxib and Diclofenac Arthritis Long-term Program (N = 34,701) comparing etoricoxib 60 or 90 mg or diclofenac 150 mg daily for a mean duration of 18 months." | 5.16 | Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs. ( Brater, DC; Cannon, CP; Curtis, SP; Gammaitoni, A; Kaur, A; Krum, H; Laine, L; Peloso, PM; Smugar, SS; Swergold, G; Wang, H; Weir, MR, 2012) |
| "We performed a multivariate analysis of 34 701 patients with arthritis receiving etoricoxib 60 or 90 mg, or diclofenac 150 mg, daily for a mean of 18 months, to assess the incidence of confirmed, adjudicated CHF events resulting in emergency room visit or hospitalization." | 5.14 | Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. ( Brater, DC; Cannon, CP; Curtis, SP; Kaur, A; Krum, H; Laine, L; Smugar, SS; Wang, H; Weir, MR, 2009) |
| "Non-steroidal anti-inflammatory drugs (NSAID) or high doses of aspirin (acetylsalicylic acid) can exert detrimental effects on renal function and counteract the beneficial effects of angiotensin-converting enzyme (ACE) inhibitors in patients with congestive heart failure." | 5.11 | Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ACE-inhibitors. ( Björkman, S; Fyge, A; Gunnarsson, B; Höglund, P; Juhlin, T; Roth, B, 2004) |
| "We evaluated 2-year CV outcomes in a prospective, nested biomarker study among patients (N = 6273) with rheumatoid arthritis and osteoarthritis treated with NSAID in the MEDAL (Multinational Etoricoxib and Diclofenac Arthritis Long-term) trial." | 3.77 | Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. ( Brune, K; Cannon, CP; Contant, CF; Curtis, SP; Jarolim, P; Kaur, A; Laine, L; Morrow, DA; Ren, F; Ruff, CT, 2011) |
| "To estimate the net cardiovascular (CV) (coronary heart disease, stroke, congestive heart failure), and gastrointestinal (GI) (peptic ulcer complications) risk-benefit public health impact of the use of celecoxib compared to non-selective NSAIDs in the arthritis population." | 3.74 | Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level. ( Castellsague, J; Maguire, A; Perez-Gutthann, S; Varas-Lorenzo, C, 2007) |
| "A 40-year-old male with Becker muscular dystrophy and cardiac involvement was stable in New York Heart Association class II for 7 years." | 1.33 | Worsening of heart failure in Becker muscular dystrophy after nonsteroidal anti-inflammatory drugs. ( Finsterer, J; Stöllberger, C, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (53.33) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Schmidt, M | 2 |
| Hallas, J | 1 |
| Ernst, MT | 1 |
| Pottegård, A | 1 |
| Franken, PR | 1 |
| Woltersdorf, R | 1 |
| Nadesalingam, K | 1 |
| Kirby, D | 1 |
| Fosbøl, EL | 1 |
| Torp-Pedersen, C | 1 |
| Olsen, AS | 1 |
| Christensen, B | 1 |
| Gislason, GH | 1 |
| Harris, D | 1 |
| Pease, N | 1 |
| Krum, H | 2 |
| Curtis, SP | 3 |
| Kaur, A | 3 |
| Wang, H | 2 |
| Smugar, SS | 2 |
| Weir, MR | 2 |
| Laine, L | 3 |
| Brater, DC | 2 |
| Cannon, CP | 3 |
| Ruff, CT | 1 |
| Morrow, DA | 1 |
| Jarolim, P | 1 |
| Ren, F | 1 |
| Contant, CF | 1 |
| Brune, K | 1 |
| Swergold, G | 1 |
| Gammaitoni, A | 1 |
| Peloso, PM | 1 |
| van der Heijden, PG | 1 |
| van Puijenbroek, EP | 1 |
| van Buuren, S | 1 |
| van der Hofstede, JW | 1 |
| Juhlin, T | 2 |
| Björkman, S | 1 |
| Gunnarsson, B | 1 |
| Fyge, A | 1 |
| Roth, B | 1 |
| Höglund, P | 2 |
| Stöllberger, C | 1 |
| Finsterer, J | 1 |
| Erhardt, LR | 1 |
| Ottosson, H | 1 |
| Jönsson, BA | 1 |
| Varas-Lorenzo, C | 1 |
| Maguire, A | 1 |
| Castellsague, J | 1 |
| Perez-Gutthann, S | 1 |
| Valat, JP | 1 |
| Deray, G | 1 |
| Héloire, F | 1 |
| Van den Ouweland, FA | 1 |
| Gribnau, FW | 1 |
| Meyboom, RH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 50 mg t.i.d. in Patients With Osteoarthritis[NCT00092703] | Phase 3 | 6,000 participants | Interventional | 2002-06-27 | Completed | ||
| A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 75 mg b.i.d. in Patients With Rheumatoid Arthritis[NCT00092742] | Phase 3 | 4,086 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients With Osteoarthritis or Rheumatoid Arthritis[NCT00250445] | Phase 3 | 23,498 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for diclofenac and Cardiac Failure
| Article | Year |
|---|---|
[Cardiovascular risks of non-steroidal anti-inflammatory drugs treatment].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Atrial Fibrillation; Blood Pressure; Cardiovascular Disease | 2016 |
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseas | 2006 |
4 trials available for diclofenac and Cardiac Failure
| Article | Year |
|---|---|
Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.
Topics: Aged; Arthritis; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib | 2009 |
Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.
Topics: Aged; Arthritis; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib | 2009 |
Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.
Topics: Aged; Arthritis; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib | 2009 |
Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.
Topics: Aged; Arthritis; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib | 2009 |
Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.
Topics: Aged; Arthritis; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib | 2009 |
Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.
Topics: Aged; Arthritis; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib | 2009 |
Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.
Topics: Aged; Arthritis; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib | 2009 |
Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.
Topics: Aged; Arthritis; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib | 2009 |
Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.
Topics: Aged; Arthritis; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib | 2009 |
Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Blood Pressure; Body Weight; Comorbidity; | 2012 |
Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ACE-inhibitors.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cr | 2004 |
Treatments with losartan or enalapril are equally sensitive to deterioration in renal function from cyclooxygenase inhibition.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2007 |
9 other studies available for diclofenac and Cardiac Failure
| Article | Year |
|---|---|
Cardiovascular risks of continuing vs. initiating NSAIDs after first-time myocardial infarction or heart failure: a nationwide cohort study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cohort Studies; Diclofenac; Heart | 2023 |
Risk of renal dysfunction in an elderly patient with chronic heart failure.
Topics: Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carvedilol; Diclofenac; Digoxin; Drug Interactio | 2016 |
Cardiovascular safety of non-steroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebrovascular Disorders; Contraindications; Diclofenac; D | 2013 |
Anti-inflammatories and heart failure-identifying patients at risk.
Topics: Analgesics, Opioid; Anti-Inflammatory Agents; Chondrosarcoma; Diclofenac; Heart Failure; Humans; Mal | 2009 |
Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein | 2011 |
On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios.
Topics: Adverse Drug Reaction Reporting Systems; Anaphylaxis; Anti-Inflammatory Agents, Non-Steroidal; Diclo | 2002 |
Worsening of heart failure in Becker muscular dystrophy after nonsteroidal anti-inflammatory drugs.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Heart Failure; Humans; Male; Muscular Dy | 2005 |
Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular D | 2007 |
Congestive heart failure due to nonsteroidal anti-inflammatory drugs in the elderly.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Female; Heart Failure; | 1988 |